topic

31 Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients
Diego de Miguel Perez, Alessandro Russo, Muthukumar Gunasekaran, Andrés Cardona, Rena Lapidus, Brandon Cooper, Sunjay Kaushal, Christine Peterson, Rivka Colen, Aung Naing, Vincenzo Adamo, Christian Rolfo

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A17-A18; DOI: 10.1136/jitc-2020-SITC2020.0031
300 Final analysis of a prospective, randomized, double-blind, placebo-controlled phase IIb trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III/IV melanoma: 36-month analysis
Lexy Adams, Robert Chick, Guy Clifton, Timothy Vreeland, Patrick McCarthy, Anne O’Shea, Phil Kemp Bohan, Annelies Hickeron, John Myers, Jessica Cindass, Diane Hale, Mark Faries, John Hyngstrom, Adam Berger, James Jakub, Jeffrey Sussman, Montaser Shaheen, Thomas Wagner, George Peoples

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A183-A184; DOI: 10.1136/jitc-2020-SITC2020.0300
301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
Paolo Ascierto, Karl Lewis, Caroline Robert, Daniil Stroyakovskiy, Helen Gogas, Svetlana Protsenko, Rodrigo Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Georgy Moiseevich Manikhas, Haocheng Li, Qian Zhu, Edward McKenna, Virginia McNally, Ralf Gutzmer, Grant McArthur

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A184-A185; DOI: 10.1136/jitc-2020-SITC2020.0301
304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma
Mohammed Milhem, Yousef Zakharia, Diwakar Davar, Elizabeth Buchbinder, Theresa Medina, Adil Daud, Antoni Ribas, Jiaxin Niu, Geoffrey Gibney, Kim Margolin, Anthony Olszanski, Inderjit Mehmi, Takami Sato, Montaser Shaheen, Aaron Morris, David Mauro, Katie Campbell, Heather Kelley, Riyue Bao, George Weiner, Jason Luke, Arthur Krieg, James Wooldridge, John Kirkwood

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A186-A187; DOI: 10.1136/jitc-2020-SITC2020.0304
306 Predictors of immunotherapy benefit in Merkel cell carcinoma
Alec Kacew, Harita Dharaneeswaran, Gabriel Starrett, Manisha Thakuria, Nicole LeBoeuf, Ann Silk, James DeCaprio, Glenn Hanna

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A188; DOI: 10.1136/jitc-2020-SITC2020.0306
322 Efficacy and safety of GX-I7 plus pembrolizumab for heavily pretreated patients with metastatic triple negative breast cancer: The Phase 1b/2 KEYNOTE-899 Study
Joo Sohn, Young Hyuk Im

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A197-A198; DOI: 10.1136/jitc-2020-SITC2020.0322
323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients
Lajos Pusztai, Hailing Lu, Christopher Hale, Anne Grosse-Wilde, Jennifer Specht, Shanu Modi, Hyo Han, Javier Cortes, Mafalda Oliveira, Phillip Garfin, Zejing Wang, Matthew Onsum

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A198-A199; DOI: 10.1136/jitc-2020-SITC2020.0323
34 Multi-step antibody validation for the geomx® digital spatial profiler
Alyssa Rosenbloom, Jenny Cronin, Shilah Bonnett

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A20-A21; DOI: 10.1136/jitc-2020-SITC2020.0034
327 Study of anti-PD-1 antibody multimodal combination as first-line treatment on time window of advanced solid tumor
Jian Shi, Baoen Shan, Junyan Wang, Jiayin Liu, Rongfeng Liu, Yujie Shan

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A200-A201; DOI: 10.1136/jitc-2020-SITC2020.0327
329 Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab
Tom Lillie, Andrew Stone, Sarah Lockwood, Richard Brown, Andrew Fox, Eirini Bournazou, John Beadle

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A202; DOI: 10.1136/jitc-2020-SITC2020.0329

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages